We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Why I Will Continue to Screen Prostate-Specific Antigen for Myself and Other Appropriate Men

David L. Keller, MSEE, MD1
[+] Author Affiliations
1Providence Medical Group, Torrance, California
JAMA Intern Med. 2014;174(1):164. doi:10.1001/jamainternmed.2013.11106.
Text Size: A A A
Published online


To the Editor The slogan “Less Is More” has an Orwellian ring to it, especially as government committees usurp the individualized decision making of clinicians. The recent editorial by Katz1 seems to imply that when a healthy 68-year-old man asks me to order a screening prostate-specific antigen (PSA) test for him, I should instead offer him an end-of-life discussion. I cannot apply results from a PSA study done on a Department of Veterans Affairs population, notorious for high rates of smoking and other bad habits, to my well-educated and health-conscious seniors who eat right, exercise, and stopped smoking in 1963. Because of their adherence to a heart-healthy lifestyle, my seniors have a longer life expectancy to protect, altering the balance of benefits and risks compared with other populations.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





January 1, 2014
Mitchell H. Katz, MD
1Los Angeles County Department of Health Services, Los Angeles, California
JAMA Intern Med. 2014;174(1):164. doi:10.1001/jamainternmed.2013.11095.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment
Further arguments in favor of screening with PSA
Posted on January 7, 2014
David Louis Keller, MS, MD
Disabled internist
Conflict of Interest: None Declared
Evidence in favor of PSA screening for prostate cancer detection was summarized in a review by Allan and colleagues (1): “Based on the best available trials, we concluded that prostate cancer screening, specifically PSA, does reduce prostate cancer mortality. The number needed to screen to prevent one prostate cancer death at nine and 14 years of follow-up were 1410 and 293, from the ERSPC and Göteborg studies, respectively.... In comparison, the number needed to screen with mammography to prevent one breast cancer death in women ≥50 years of age is 1235 and 614 for 7 and 13 years, respectively. The number needed to screen with fecal occult blood testing to prevent one colorectal cancer death is 617 over 12 to 18 years. Prostate cancer screening, similar to the other accepted cancer screening programs, does not modify overall mortality.\"Note that in the Goteborg study, 24% of the men invited to be screened never actually showed up to have a PSA drawn, yet they were included in the intention-to-treat analysis. If we subtract them from the results, then the number actually screened to prevent one death is reduced to 223. In the PLCO prostate cancer screening study, 52% of the “control” patients actually had PSA testing performed outside the study, and only 86% of patients in the screening arm were compliant with the PSA protocol. This severely contaminated data did not support PSA screening, which tells us little except to disregard any meta-analysis which includes PLCO.In my letter, I pointed out that clinicians can improve the specificity of PSA screening by the following technique: when an elevated PSA occurs, repeat it a few times at short intervals and discard all but the lowest PSA for comparison to the biopsy threshold. This simple technique can spare many men from undergoing prostate biopsies, reducing potential harms from screening.Arguments against PSA screening often cite patient worry as a potential harm, which actually represents failure by clinicians to communicate the indolent behavior of many prostate cancers. Men offered screening should be informed that prostate cancers exhibit a range of behaviors, and often do not result in metastases or death. Dr. Katz states that only 7% of men chose watchful waiting for localized prostate cancer in a recent registry, while 83% chose invasive treatments, despite the lack of convincing data to support the superiority of the latter. This again represents a failure of communication by the physicians involved. Patients are generally quite happy to avoid surgery when their clinician assures them it is not necessary or beneficial. We can increase the use of watchful waiting if we communicate effectively with our patients.Finally, I wish to correct an omission from the last paragraph of my letter, which should have read: “We need a large trial of PSA measured every 3 months during the first year (to establish a baseline PSA)....” 1: Allan GM, Chetner MP, Donnelly BJ, Hagen NA, Ross D, Ruether JD, Venner P.Furthering the prostate cancer screening debate (prostate cancer specificmortality and associated risks). Can Urol Assoc J. 2011 Dec;5(6):416-21. doi:10.5489/cuaj.11063. PubMed PMID: 22154638; PubMed Central PMCID: PMC3235209.
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...